Pliant Therapeutics Inc

PLRXNASDAQ · USD
1.05USD+0.02 (+0.97%)
735

Pliant Therapeutics Inc (PLRX) Straddle

PLRX straddle scan found 1 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 85.7%.

Read more

Trading a PLRX straddle lets you take a pure volatility position on Pliant Therapeutics Inc without committing to a direction. Pliant Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate PLRX straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on PLRX profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Pliant Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the PLRX straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the PLRX straddle is the cleanest expression of that view. Our scanner prices every PLRX straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a PLRX straddle into a catalyst or short a PLRX straddle to harvest decay, the options straddle setups that matter are all in one place.

Apr 16, 20272.50$2.0519681%85.7%$4.55$0.450

As of October 2, 2026

Find the right straddle before volatility moves

Track PLRX straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial